Tuesday’s Top Health Care Stories: BioCryst, Durata, Bristol-Myers Squibb, and Incyte

BioCryst, Durata, Bristol-Myers Squibb, and Incyte could all loom large in health care headlines today. Here’s why.

May 27, 2014 at 9:25AM


Let's take a quick look at four stocks -- BioCryst (NASDAQ:BCRX), Durata Therapeutics (NASDAQ:DRTX), Bristol-Myers Squibb (NYSE:BMY), and Incyte (NASDAQ:INCY) -- which could all make health care headlines this Tuesday morning.

BioCryst surges on positive results for BCX4161
Shares of BioCryst are up more than 23% in pre-market trading today, after the company announced that its experimental drug, BCX4161, was effective at reducing attacks of hereditary angioedema (HAE) -- a rare genetic disease characterized by sudden swelling of the skin -- when compared to placebo. BioCryst stated that patients given the drug during a mid-stage trial had an average rate of 0.82 attacks per week, compared to 1.27 attacks for the placebo group.

Of the four main HAE treatments on the market -- Shire's (NASDAQ:SHPG) Cinryze and Firazyr, Dyax's Kalbitor, and CSL Behring's Berinert -- only Cinryze is administered as a preventative measure. The other three drugs are only administered when attacks occur.

Therefore, BCX4161 could become a major competitor for Cinryze, which Shire acquired through its $4.2 billion acquisition of ViroPharma last year. Last quarter (which included its first two months of owning Cinryze), Shire reported $85.6 million in Cinryze sales. Analysts at JPMorgan believe that Cinryze could eventually generate peak sales north of $700 million. Hopes are even higher for BioCryst's BCX4161 -- Roth Capital Partner analysts believe that sales could hit $1 billion by 2023.

Durata slides following the approval of Dalvance
Shares of Durata Therapeutics were down more than 23% in pre-market trading today, possibly a case of profit-taking following the FDA approval of the company's first marketed drug, Dalvance, last Friday. Prior to the approval, shares of Durata had rallied 45% since April 14, when it hit a low of $11.68. Shares have since recovered to a more moderate pre-market loss of 6%.

Dalvance is a treatment for a serious ABSSSI (acute bacterial skin and skin structure infections) -- which can include deep tissue infections, Gram-positive infections, and infections associated with underlying diseases such as diabetes. The drug is expected to generate peak sales of $446 million by 2019, according to Thomson Reuters estimates. Prior to the drug's approval, it demonstrated non-inferiority when compared to vancomycin, a treatment which is available in generic form, and vancomycin followed by Pfizer's Zyvox (linezolid).

The company finished last quarter with $41.5 million in cash and equivalents -- a 30% decline from the prior year quarter. The company reported a GAAP net loss of $20 million, down from a narrower loss of $15.8 million a year earlier. Durata attributed the wider losses to higher general and adminstrative expenses related to the upcoming launch of Dalvance.

Bristol-Myers Squibb and Incyte announce a new collaboration
Bristol-Myers Squibb and Incyte just entered an agreement to evaluate the safety, tolerability, and preliminary efficacy of a combination regimen consisting of Bristol-Myers' nivolumab and Incyte's INCB24360 for multiple tumor types.

Nivolumab is a PD-1 immune checkpoint inhibitor, a type of immunotherapy which attempts to elicit an immune system response to fight cancerous cells. Nivolumab received an FDA Breakthrough Therapy Designation for Hodgkin Lymphoma earlier this month, which will expedite its review process. If approved, nivolumab is expected to generate peak sales as high as $6 billion.

INCB24360 is an oral indoleamine dioxygenase-1 inhibitor, and is currently testing the drug in eight early stage trials for various types of cancers.

This is not the first time Incyte has collaborated with a larger partner to test INCB24360 as part of a combination regimen. In February, Incyte entered an agreement with Merck to evaluate INCB24360 alongside Merck's MK-3475 immunotherapy in an early stage study for non-small cell lung cancer. Earlier this month, Incyte announced a collaboration with AstraZeneca to study a combination of INCB24360 with AstraZeneca's MEI4736 immunotherapy in treating multiple solid tumors.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers